Showing results (31-40 of 61) with videos related to

Sort By:
Pageof 7
Cancers|October 26, 2024
Comparing Lenvatinib/Pembrolizumab with Atezolizumab/Bevacizumab in Unresectable Hepatocellular Carcinoma: A Real-World Experience with Propensity Score Matching AnalysisYu-Chun Hsu, Po-Ting Lin, Wei Teng, et al.
American Journal of Cancer Research|December 7, 2023
A combination of locoregional treatment with systemic therapy after atezolizumab plus bevacizumab failure for unresectable hepatocellular carcinoma provides survival benefitChung-Wei Su, Wei Teng, Po-Ting Lin, et al.
Journal of Cancer|June 22, 2026
<i>GALNT14</i>-rs9679162 Genotypes Predict Post-immunotherapy Side Effect and Survival in Patients with Hepatitis B Virus-related Hepatocellular CarcinomaPo-Ting Lin, Wei Teng, Wei-Ting Chen, et al.
Cancer Immunology, Immunotherapy : CII|January 27, 2026
Non-thyroidal illness syndrome predicts poor prognosis in hepatocellular carcinoma patients treated with atezolizumab and bevacizumabI-Wen Chen, Cheng-Wei Lin, Po-Ting Lin, et al.
Cancers|October 16, 2025
Moderate Immune-Related Liver Injury Is a Good Factor in Patients with Hepatoma Under Atezolizumab Plus BevacizumabTai-Chi Wu, Po-Ting Lin, Wei Teng, et al.
Frontiers in Oncology|October 17, 2022
The combination of sarcopenia and biochemical factors can predict the survival of hepatocellular carcinoma patients receiving transarterial chemoembolizationTzu-Ping Chien, Song-Fong Huang, Wen-Hui Chan, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|July 10, 2025
Tumor size larger than 6.5 cm and microvascular invasion are comparable prognosticators for hepatocellular carcinoma: a multi-institutional observational studyHsing-Yu Chen, Hsin-I Tsai, Ming-Chin Yu, et al.
European Journal of Gastroenterology & Hepatology|December 19, 2019
Add-on sorafenib is beneficial for hepatocellular carcinoma patients with transarterial chemoembolization refractoriness: a real-world experiencePo-Ting Lin, Wei Teng, Wen-Juei Jeng, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|September 10, 2019
The incidence and predictors of post transarterial chemoembolization variceal bleeding in hepatocellular carcinoma patientsPo-Ting Lin, Wei Teng, Wen-Juei Jeng, et al.
American Journal of Cancer Research|April 9, 2024
Locoregional treatment improves overall survival for liver cancer during second-line regorafenib or immune checkpoint inhibitorPo-Ting Lin, Yu-Chun Hsu, Yu-Ting Kao, et al.
Pageof 7